OnabotulinumtoxinA in Migraine and Other Headaches: Review and Update

Marc E Lenaerts, Tiffany H. Green

Research output: Contribution to journalReview article

Abstract

Purpose of the review: The role of onabotulinumtoxinA in headache management was serendipitously found over a decade ago and approved for chronic migraine in 2010 based on pivotal studies. The purpose of this review is to highlight the impact on headache and other health parameters which is critically reviewed, as well as the putative mechanisms of action. Recent findings: OnabotulinumtoxinA is effective in migraine, not only headache frequency and pain intensity but also other health parameters including quality of life. Tolerability is high and benefit/cost analysis is favorable. It should be considered off-label in refractory trigeminal neuralgia and post-herpetic neuralgia but further research in these areas. Ongoing investigation of onabotulinumtoxinA in cluster headache is too preliminary for recommendation of use but promising. Recent and future developments in other headache disorders are discussed. Summary: OnabotulinumtoxinA has been approved for migraine almost a decade ago and been proven beneficial not only on headache parameters but other health outcomes. Its role as adjuvant is being studied and emerging in other headache syndromes.

Original languageEnglish (US)
Article number21
JournalCurrent Treatment Options in Neurology
Volume21
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Migraine Disorders
Headache
Headache Disorders
Health
Cluster Headache
Trigeminal Neuralgia
Neuralgia
Cost-Benefit Analysis
Quality of Life
Pain
onabotulinumtoxinA
Research

Keywords

  • Cluster headache
  • Headache
  • Migraine
  • OnabotulinumtoxinA
  • Trigeminal neuralgia

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

OnabotulinumtoxinA in Migraine and Other Headaches : Review and Update. / Lenaerts, Marc E; Green, Tiffany H.

In: Current Treatment Options in Neurology, Vol. 21, No. 4, 21, 01.04.2019.

Research output: Contribution to journalReview article

@article{1aa8905a6a1e4900a606d4ab45ca812a,
title = "OnabotulinumtoxinA in Migraine and Other Headaches: Review and Update",
abstract = "Purpose of the review: The role of onabotulinumtoxinA in headache management was serendipitously found over a decade ago and approved for chronic migraine in 2010 based on pivotal studies. The purpose of this review is to highlight the impact on headache and other health parameters which is critically reviewed, as well as the putative mechanisms of action. Recent findings: OnabotulinumtoxinA is effective in migraine, not only headache frequency and pain intensity but also other health parameters including quality of life. Tolerability is high and benefit/cost analysis is favorable. It should be considered off-label in refractory trigeminal neuralgia and post-herpetic neuralgia but further research in these areas. Ongoing investigation of onabotulinumtoxinA in cluster headache is too preliminary for recommendation of use but promising. Recent and future developments in other headache disorders are discussed. Summary: OnabotulinumtoxinA has been approved for migraine almost a decade ago and been proven beneficial not only on headache parameters but other health outcomes. Its role as adjuvant is being studied and emerging in other headache syndromes.",
keywords = "Cluster headache, Headache, Migraine, OnabotulinumtoxinA, Trigeminal neuralgia",
author = "Lenaerts, {Marc E} and Green, {Tiffany H.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s11940-019-0561-6",
language = "English (US)",
volume = "21",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - OnabotulinumtoxinA in Migraine and Other Headaches

T2 - Review and Update

AU - Lenaerts, Marc E

AU - Green, Tiffany H.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose of the review: The role of onabotulinumtoxinA in headache management was serendipitously found over a decade ago and approved for chronic migraine in 2010 based on pivotal studies. The purpose of this review is to highlight the impact on headache and other health parameters which is critically reviewed, as well as the putative mechanisms of action. Recent findings: OnabotulinumtoxinA is effective in migraine, not only headache frequency and pain intensity but also other health parameters including quality of life. Tolerability is high and benefit/cost analysis is favorable. It should be considered off-label in refractory trigeminal neuralgia and post-herpetic neuralgia but further research in these areas. Ongoing investigation of onabotulinumtoxinA in cluster headache is too preliminary for recommendation of use but promising. Recent and future developments in other headache disorders are discussed. Summary: OnabotulinumtoxinA has been approved for migraine almost a decade ago and been proven beneficial not only on headache parameters but other health outcomes. Its role as adjuvant is being studied and emerging in other headache syndromes.

AB - Purpose of the review: The role of onabotulinumtoxinA in headache management was serendipitously found over a decade ago and approved for chronic migraine in 2010 based on pivotal studies. The purpose of this review is to highlight the impact on headache and other health parameters which is critically reviewed, as well as the putative mechanisms of action. Recent findings: OnabotulinumtoxinA is effective in migraine, not only headache frequency and pain intensity but also other health parameters including quality of life. Tolerability is high and benefit/cost analysis is favorable. It should be considered off-label in refractory trigeminal neuralgia and post-herpetic neuralgia but further research in these areas. Ongoing investigation of onabotulinumtoxinA in cluster headache is too preliminary for recommendation of use but promising. Recent and future developments in other headache disorders are discussed. Summary: OnabotulinumtoxinA has been approved for migraine almost a decade ago and been proven beneficial not only on headache parameters but other health outcomes. Its role as adjuvant is being studied and emerging in other headache syndromes.

KW - Cluster headache

KW - Headache

KW - Migraine

KW - OnabotulinumtoxinA

KW - Trigeminal neuralgia

UR - http://www.scopus.com/inward/record.url?scp=85063999543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063999543&partnerID=8YFLogxK

U2 - 10.1007/s11940-019-0561-6

DO - 10.1007/s11940-019-0561-6

M3 - Review article

AN - SCOPUS:85063999543

VL - 21

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 4

M1 - 21

ER -